(HealthDay)—High levels of physical activity may lower the risk for developing lymphoma, according to a review/meta-analysis published online Oct. 6 in BMC Cancer.
Oct 14, 2020
0
4
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used ...
Oct 8, 2020
0
2
Targeting a "cell survival" protein could be a valuable new approach to treating certain blood cancers associated with Epstein-Barr virus (EBV), according to research resulting from a collaboration between scientists at the ...
Oct 7, 2020
0
23
The National Comprehensive Cancer Network (NCCN) today announced the publication of new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Hodgkin Lymphoma. Hodgkin lymphoma is one of the most curable ...
Sep 28, 2020
0
3
Lymphomas are a diverse group of cancers of the immune system, which is the body's primary defense against autoimmune disease, infections, and malignancy. Now, researchers at the University of Tsukuba have clarified risk ...
Sep 16, 2020
0
9
The National Institute for Health and Care Excellence (NICE) has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England.
Aug 21, 2020
0
1
A study has found strong similarities between children withendemic Burkitt lymphoma—an aggressive cancer that attacks the body's defense system and children with silent malaria infection.
Aug 11, 2020
0
0
Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) and The Ohio State University Wexner Medical Center are conducting ...
Jul 29, 2020
0
3
(HealthDay)—For patients with diffuse large B-cell lymphoma (DLBCL), the combination of low muscle mass (LMM) and low muscle density (LMD) is an independent prognostic factor for survival, according to a study published ...
Jul 28, 2020
0
1
Today's Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber ...
Jul 24, 2020
0
3
